Table 2.
Prognostic factors for molecular RFS after TKI discontinuation
| Univariate analysis | Multivariate analysis | |||||||
|---|---|---|---|---|---|---|---|---|
| Variables | 1-year RFS, % (± SE) | p-value | HR | 95% CI | p-value | |||
| Age | ≥ 49 years | 61.9 (± 10.6) | 0.115 | |||||
| < 49 years | 36.8 (± 11.1) | |||||||
| Gender | Male | 45.0 (± 11.1) | 0.406 | |||||
| Female | 55.0 (± 11.1) | |||||||
| WBC at TKI stop | ≥ 100,000/µL | 28.6 (± 12.1) | 0.065 | |||||
| < 100,000/µL | 64.0 (± 9.6) | |||||||
| BCR::ABL1 | E14a2 | 64.3 (± 9.1) | < 0.001 | 1 | < 0.001 | |||
| transcript type | E13a2 | 0 | 7.249 | 2.682–19.594 | ||||
| BCR::ABL1 IS at 3 | ≥ 10% | 42.9 (± 18.7) | 0.719 | |||||
| months, % | < 10% | 50.0 (± 9.4) | ||||||
| TKI treatment line | 1 st line | 46.4 (± 9.4) | 0.598 | |||||
| 2nd or 3rd line | 58.3 (± 14.2) | |||||||
| TKI type at stop | 1 st generation | 40.0 (± 21.9) | 0.898 | |||||
| 2nd generation | 51.4 (± 8.4) | |||||||
| Duration of TKI | ≥ 70 months | 61.9 (± 10.6) | 0.068 | |||||
| treatment | < 70 months | 36.8 (± 11.1) | ||||||
| Duration of DMR | ≥ 50 months | 63.6 (± 10.3) | 0.031 | 1 | 0.005 | |||
| before TKI stop | < 50 months | 33.3 (± 11.1) | 3.829 | 1.487–9.858 | ||||
| RT-qPCR values | 0.0032%<BCR::ABL1 IS≤0.01% | 28.6 (± 17.1) | 0.210 | |||||
| at TKI stop | BCR::ABL1 IS≤0.0032% | 54.5 (± 8.7) | ||||||
Abbreviations: TKI, tyrosine kinase inhibitor; RFS, relapse-free survival; SE, standard error; HR, hazard ratio; CI, confidence interval; WBC, white blood cell; IS, International Scale; DMR, deep molecular response; RT-qPCR, reverse transcription-quantitative polymerase chain reaction